→ Voyager Therapeutics $VYGR is hunting for a new CEO as co-founder and current chief executive Steven Paul has decided to focus on preclinical discovery research and portfolio development. After six years on the front line, he will transition to the role of executive science advisor and stay on both the board and the science & tech committee. Paul, an Eli Lilly vet, was a venture partner at Third Rock when he helped form the biotech, known for its gene therapy for Parkinson’s disease.
→ Alnylam’s lead drug patisiran just got one step closer to approval: the FDA has accepted the biotech’s $ALNY NDA filing and granted the drug priority review to speed things along. That’s in addition to previous breakthrough therapy and fast track designations. The Cambridge/Boston RNAi specialist has expressed much confidence in patisiran for hereditary ATTR amyloidosis, having restructured its deal with Sanofi to re-gain global rights just ahead of the JP Morgan health care conference in January. An approval — by the PDUFA date of August 11 — is widely expected.
→ Waltham, MA-based Syndax Pharmaceuticals is collaborating with AstraZeneca on a combo using AZ’s PD-L1 durvalumab with SNDX-6352, Syndax’s monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor (CSF1R), across a variety of solid tumors.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription